Loading…
Loading…
Issued jointly by Huangpu District's Science and Technology Commission and Investment Promotion Office (the same two-agency pairing that issued the district's translational-medicine measure five days later on 30 December, filed as 2025-12-25-shanghai-huangpu-translational-medicine-subsidy), this is a district-level supply-side subsidy stack dedicated specifically to brain-computer interface (BCI) hardware and medical-device commercialisation — branded locally as the "BCI Service 10 Provisions" (脑机接口服务十条). It covers the full BCI value chain in nine instrument lines:
match capped at 1:1 against national/municipal BCI project funding.
(capped CNY 2m) for BCI-specific labs and shared technology platforms.
40% of R&D cost for devices that have completed regulatory registration, capped at CNY 5m/year per entity.
(capped CNY 2m) for BCI deployment/demo projects.
strong market response.
recognition upgrades.
of BCI-focused industrial clusters with demonstrated agglomeration effect.
firms that have raised at least CNY 20m in equity funding.
hosting globally or nationally influential BCI conferences.
Funding is disbursed on a reimbursement basis — applicants invest first and are repaid after verification of results, the same post-hoc structure used in the district's translational-medicine measure.
district-level measure sits beneath the Shanghai Municipal Science and Technology Commission's "BCI Future Industry Cultivation Action Plan 2025-2030" (沪科〔2025〕5号) and the Shanghai Medical Insurance Bureau/Health Commission's trial BCI medical-service pricing notice (沪医保价采发〔2025〕26号) — neither yet on the register — indicating Shanghai is building a full municipal-to-district BCI policy stack (R&D finance → reimbursement pricing → district commercialisation subsidy) in parallel, consistent with the broader pattern of granular sub-national industrial-policy layering also seen in the district's translational-medicine measure.
entity for registered-device reimbursement (40% of R&D cost), this line dwarfs the R&D/platform grants (CNY 2m) — the district is weighted toward pulling BCI devices through regulatory registration and into market rather than funding early research, mirroring the sister translational-medicine measure's emphasis on late-stage de-risking. China's BCI sector is nascent globally (no jurisdiction has a mature BCI device-approval track record), so a district explicitly subsidising the registration-to-market step is a leading indicator of where Beijing expects first-mover regulatory and commercial advantage to be built.
medicine measure and State Council Order 818 (national biomedical new-technology framework) when assessing cumulative Chinese state aid to biotech/medtech for EU Foreign Subsidies Regulation or Section 301-style overcapacity arguments.
caps are disclosed, not an aggregate district appropriation.
disclosed yet; watch Huangpu district government announcements for first grant-recipient lists once the measure's reimbursement cycle matures.
awardees can stack district subsidies with the municipal 沪科〔2025〕5号 action-plan funding, or whether the two are mutually exclusive by project — not disclosed in the notice text reviewed.